A recent study published in JAMA Network Open has raised alarms about a potential link between the GLP-1 drugs Ozempic and Wegovy, which contain semaglutide, and an increased rate of suicidal thoughts among patients. The analysis of the World Health Organization's database revealed a higher incidence of suicidal ideation in those taking semaglutide compared to other diabetes and obesity medications. However, the overall reports of suicidal thoughts were low, accounting for only 0.3% of adverse reactions, and no increased risk of suicide attempts was found. Experts have criticized the study's findings, citing limitations such as reliance on self-reported data and potential biases. The FDA and European Medicines Agency have previously stated that there is no conclusive evidence linking these drugs to suicidal thoughts, but investigations are ongoing. The findings underline the need for caution among physicians when prescribing these drugs, especially to patients with a history of mental health issues.